Loading…
← CockpitCompetitor Analysis › 300204.SZ Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class AOpen in the cockpit ↗

Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A300204.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Beijing biologics maker known for recombinant nerve growth factor drugs treating neurological injuries and neuropathy.

≈ A small, single-product Chinese biologics makerMomentum laggard 10
Mkt cap
$1.26B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$24.2M
20-day average traded
Fwd P/E
522.3×
forward earnings
ROIC−WACC
-16.3 pp
WACC 10.1%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥15.92
1D-1.4%
1W-10.9%
1M-12.4%
3M-38.3%
6M-41.3%
YTD-41.7%
1Y-58.2%
ATR %5.1%
52w lowhigh60.6% off high

What Staidson (Beijing) Biopharmaceuticals does

Beijing biologics maker known for recombinant nerve growth factor drugs treating neurological injuries and neuropathy.

In one line: A small, single-product Chinese biologics maker.

Products and services

  • Recombinant human nerve growth factor

Where it sits in the supply chain

  • Pharmaceuticals
  • Biologics
  • Neurology therapeutics

Moat: narrow (IP / patents, regulatory licence). One of few approved nerve-growth-factor biologics in China, protecting near-term market share.

Headquarters: Beijing, China · Employees: 491

Staidson (Beijing) Biopharmaceuticals at a glance

Size Staidson (Beijing) Biopharmaceuticals (300204.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.26B, the 1771st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.92 on 18 Nov 2026.

Performance Over six months the shares fell 41.3%, against -9.6% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue fell 23.5% over the last twelve months (peer median +3.1%); the operating margin is -51.2% (peer median 0.8%).

Valuation It trades at 522.3× forward earnings against a peer median of 20.0× (most expensive of 11).

Capital Return on invested capital runs 16.3 points below its cost of capital (10.1% WACC).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 86300204.SZ 60
Six months, rebased to 100: Staidson (Beijing) Biopharmaceuticals against the median of its 20 peers (local-currency closes).

Staidson (Beijing) Biopharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥187MCN¥219MCN¥323MCN¥360MCN¥542M
Revenue growth—-32%-10%-34%—
Gross profitCN¥150MCN¥160MCN¥246MCN¥275MCN¥418M
EBITDAn/a-CN¥58.9M-CN¥21.0M-CN¥340M-CN¥224M
Net income-CN¥99.5M-CN¥77.8M-CN¥145M-CN¥399M-CN¥197M
Free cash flow-CN¥187M-CN¥202M-CN¥86.7M-CN¥260M-CN¥226M
Capital expenditureCN¥113MCN¥76.6MCN¥23.5MCN¥32.2MCN¥56.5M
Total debtCN¥760,797CN¥301MCN¥42.5MCN¥41.0MCN¥29.0M

Quarterly statements and history in the cockpit →

Staidson (Beijing) Biopharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%GHRS688076AMPHGPCR002332AVLNIDIALBRX347850OCULINVAMNKDHROW2616300006300204.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Staidson (Beijing) Biopharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×200×400×688076AMPH000950300026301263MNKDHROW688293300204.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Staidson (Beijing) Biopharmaceuticals is the large dot.

Staidson (Beijing) Biopharmaceuticals competitors and peer comparison

How Staidson (Beijing) Biopharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Staidson (Beijing) Biopharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure300204.SZPeer medianRank in peer set
1-month return-12.4%-4.8%3rd lowest of 20
6-month return-41.3%-9.6%3rd lowest of 20
Distance from 52-week high-60.6%-37.1%4th lowest of 20
Revenue growth (TTM)-23.5%+3.1%3rd lowest of 16
Operating margin-51.2%0.8%5th lowest of 16
Forward P/E522.3×20.0×most expensive of 11
ROIC minus cost of capital-16.3 pp-4.8 pp4th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%21.3×7.0%-5.3%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%n/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%60.7×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%n/an/an/a
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%n/an/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%9.5×-17.2%+3.9%
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a
Harrow HROWUnited States$1.21B+4%+21%1%26.8×n/an/a
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%n/an/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%n/a44.1%-13.2%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%48.6×25.9%+23.1%

Questions

Which companies are Staidson (Beijing) Biopharmaceuticals's closest peers?
The cockpit's peer set: GH Research (GHRS), Sinopep-Allsino Bio Pharmaceutical (688076.SS), Amphastar Pharmaceuticals (AMPH), C.Q. Pharmaceutical (000950.SZ), Structure Therapeutics, Inc. Sponsored ADR (GPCR), Zhejiang Xianju Pharmaceutical (002332.SZ), Avalyn Pharma (AVLN), Tianjin Chase Sun Pharmaceutical (300026.SZ).
Is Staidson (Beijing) Biopharmaceuticals expensive compared with its peers?
On forward p/e it trades at 522.3× against a peer median of 20.0×, most expensive of 11 in its peer set.
How has Staidson (Beijing) Biopharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -41.3% against -9.6% for the median peer; over one year -58.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.